Triptorelin
Trials 113 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03511196 | Sep 2018 → Jun 2022 overdue | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04189900 | Apr → May 2019 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07653282 | Aug 2026 → Aug 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04616729 | Nov 2022 → Nov 2025 | female breast carcinoma | University Hospital Brussels | Unknown | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT07569302 | Jun 2026 → Dec 2027 expected | infertility disorder | Bedaya Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07569315 | Jun 2026 → Dec 2027 expected | infertility disorder | Bedaya Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07569289 | Jun 2026 → Dec 2027 expected | infertility disorder | Bedaya Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07455903 | Apr 2026 → Oct 2029 expected | prostate carcinoma | Baptist Health South Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT06225284 | Aug 2024 → Dec 2026 expected | triple-negative breast carcinoma | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05896566 | Jan 2024 → Sep 2025 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 2 | NCT06146413 | Dec 2023 → Mar 2025 | infertility disorder | Bedaya Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04407065 | May → Dec 2020 | female infertility | Riyadh Fertility and Reproductive Health center | Unknown | No outcome recorded |
| Phase 2 | NCT04407052 | May → Dec 2020 | female infertility | Riyadh Fertility and Reproductive Health center | Unknown | No outcome recorded |
| Phase 2 | NCT03536234 | Sep 2018 → Aug 2021 | HIV infectious disease | Immune System Regulation AB | Unknown | No outcome recorded |
| Phase 2 | NCT02972060 | Dec 2017 → Jan 2023 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03279250 | Oct 2017 → May 2021 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04659551 | Oct 2017 → May 2020 | breast cancer | Veneto Institute of Oncology IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT01969578 | Sep 2015 → Aug 2023 | salivary gland cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT02244151 | Sep 2014 → Feb 2018 | female reproductive system disorder | La Fe Health Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02005887 | Feb 2014 → Aug 2017 | invasive breast carcinoma | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02113553 | May 2013 → May 2016 | breast cancer | Armando Santoro, MD | Terminated | No outcome recorded |
| Phase 2 | NCT03397537 | Sep 2012 → Jul 2017 | hormone receptor-positive breast cancer | Guangdong Provincial People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01374087 | Nov 2011 → Dec 2014 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 2 | NCT01257425 | Dec 2010 → Feb 2012 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 2 | NCT00528866 | Apr 2008 → Dec 2013 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00444639 | Feb 2007 → Feb 2008 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 2 | NCT00090844 | Jul 2004 → May 2008 | breast cancer, poisoning | University of South Florida | Terminated | No outcome recorded |
| Phase 2 | NCT00124514 | Jun 2003 → Mar 2014 | systemic lupus erythematosus | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07319429 | Jan 2026 → Dec 2027 expected | endometrial cancer, infertility disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04753177 | Jan 2021 → Jan 2023 | — | Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary | Unknown | No outcome recorded |
| Phase 2/3 | NCT02856048 | Nov 2016 → Feb 2021 | Ewing sarcoma, chemotherapy-induced toxicity, lymphoma, osteosarcoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2/3 | NCT01603420 | Jul 2012 → May 2014 | prostate cancer | Proton Collaborative Group | Terminated | No outcome recorded |
| Phase 2/3 | NCT01160315 | Jul 2002 → Jun 2010 | lymphoma, primary ovarian failure | Erasme University Hospital | Completed | No outcome recorded |
| Phase 338 trials | ||||||
| Phase 3 | NCT06795178 | Jul 2025 → Dec 2027 | prostate cancer | Foresee Pharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT06795191 | Jun 2025 → Nov 2027 | prostate cancer | Foresee Pharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 3 | NCT06513962 | Feb 2025 → Oct 2029 expected | cancer, hematopoietic and lymphoid system neoplasm | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT06150703 | Jun 2024 → Sep 2027 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05328258 | Mar 2023 → Jan 2028 expected | Ewing sarcoma, acute leukemia, female breast carcinoma, lymphoma +2 | Kenny Rodriguez-Wallberg | Recruiting | No outcome recorded |
| Phase 3 | NCT05590793 | Nov 2022 → Aug 2024 | metastatic prostate carcinoma | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT05458856 | Aug 2022 → Jul 2024 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT05397795 | Jun → Dec 2022 | infertility disorder | Alexandria University | Unknown | No outcome recorded |
| Phase 3 | NCT03940807 | Apr 2022 → Jan 2025 | adenomyosis | University Hospital, Toulouse | Withdrawn | No outcome recorded |
| Phase 3 | NCT05029622 | Aug 2021 → Aug 2022 | central precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT04736602 | Mar 2021 → Feb 2022 | central precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT03809429 | Apr 2019 → Feb 2022 | female infertility | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04224818 | Jul 2018 → Aug 2019 | ovarian dysfunction | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03232281 | Jul 2017 → May 2019 | endometriosis | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT02732808 | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT02053779 | Mar 2014 → Mar 2017 | infertility disorder | Centre Hospitalier Universitaire Ibn Rochd | Completed | No outcome recorded |
| Phase 3 | NCT03039049 | Mar 2014 → Mar 2017 | infertility disorder | Centre Hospitalier Universitaire Ibn Rochd | Completed | No outcome recorded |
| Phase 3 | NCT01715129 | Jan → Oct 2013 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT01656161 | Jul 2012 → Aug 2013 | prostate cancer | Debiopharm International SA | Completed | No outcome recorded |
| Phase 3 | NCT01467882 | Apr 2012 → Aug 2013 | central precocious puberty | Debiopharm International SA | Completed | No outcome recorded |
| Phase 3 | NCT01492972 | Jan 2012 → Dec 2027 expected | prostate cancer | Proton Collaborative Group | Recruiting | No outcome recorded |
| Phase 3 | NCT01368588 | Jul 2011 → Apr 2025 overdue | prostate cancer | Radiation Therapy Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01020448 | Nov 2009 → Nov 2011 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00936390 | Sep 2009 → Oct 2020 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00667069 | Apr 2008 → Apr 2020 | prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00909844 | Apr 2008 → Apr 2015 | precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00567580 | Feb 2008 → Jul 2018 | prostate cancer | Radiation Therapy Oncology Group | Unknown | No outcome recorded |
| Phase 3 | NCT00659373 | Dec 2007 → Dec 2014 | breast cancer, sleep disorder | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00564850 | Oct 2007 → Oct 2010 | precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00415246 | Nov 2006 → Oct 2007 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 3 | NCT01007851 | Sep 2006 → Dec 2007 | infertility disorder | V.K.V. American Hospital, Istanbul | Terminated | No outcome recorded |
| Phase 3 | NCT00751790 | Jul 2006 → Aug 2007 | prostate neoplasm | Debiopharm International SA | Completed | No outcome recorded |
| Phase 3 | NCT00066690 | Dec 2003 → May 2014 | estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00104741 | Sep 2003 → Oct 2015 | prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00311636 | Sep 2003 → Jan 2008 | breast cancer | Gruppo Italiano Mammella (GIM) | Completed | No outcome recorded |
| Phase 3 | NCT00066807 | Aug 2003 → Dec 2006 | breast cancer | ETOP IBCSG Partners Foundation | Terminated | No outcome recorded |
| Phase 3 | NCT00003734 | Dec 1998 → ? | prostate cancer | St. Luke's Hospital, Ireland | Unknown | No outcome recorded |
| Phase 3 | NCT00003026 | Apr 1997 → Sep 2001 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 426 trials | ||||||
| Phase 4 | NCT07696351 | Aug 2025 → Dec 2026 expected | endometriosis, infertility disorder | Li-jun Ding | Recruiting | No outcome recorded |
| Phase 4 | NCT06487143 | Jul 2024 → Dec 2026 expected | central precocious puberty | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05286554 | Mar 2022 → Oct 2023 | female infertility | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT04248621 | Jan 2020 → Apr 2022 | prostate neoplasm | Wonju Severance Christian Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03809221 | Feb 2019 → Sep 2020 | female infertility | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03169166 | Mar 2017 → Jul 2021 | female infertility | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02715232 | Feb 2017 → Dec 2020 | body integrity dysphoria | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT03115307 | Jan 2017 → Nov 2019 | female infertility | Tampere University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02825290 | Jul 2016 → Jun 2017 | — | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02655146 | Dec 2015 → Dec 2016 | infertility disorder | Chong Qing Reproducive and Genetic Institute | Unknown | No outcome recorded |
| Phase 4 | NCT02201914 | Jan → Oct 2014 | — | Bioroma | Unknown | No outcome recorded |
| Phase 4 | NCT02070198 | Dec 2013 → Nov 2014 | female infertility | Bioroma | Unknown | No outcome recorded |
| Phase 4 | NCT02620124 | May 2013 → Apr 2015 | infertility disorder | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01714648 | Nov 2012 → Jan 2014 | ovarian hyperstimulation syndrome | Elisha Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01638026 | Sep 2012 → Jul 2017 | infertility disorder | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| Phase 4 | NCT01673984 | Aug 2012 → Feb 2014 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 4 | NCT01500863 | Nov 2011 → May 2012 | ovarian hyperstimulation syndrome | IVI Madrid | Completed | No outcome recorded |
| Phase 4 | NCT00735852 | Dec 2008 → May 2016 | endometriosis | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT00840944 | Jan 2008 → Jan 2024 | isolated short stature | Belgian Study Group for Pediatric Endocrinology | Unknown | No outcome recorded |
| Phase 4 | NCT00417183 | Sep 2005 → Jun 2007 | infertility disorder | Eugonia | Unknown | No outcome recorded |
| Phase 4 | NCT00461916 | May 2005 → Dec 2006 | infertility disorder | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00503217 | Feb 2005 → Dec 2007 | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 4 | NCT00415792 | Nov 2003 → Jul 2005 | infertility disorder | Eugonia | Unknown | No outcome recorded |
| Phase 4 | NCT00417144 | Nov 2003 → May 2007 | ovarian hyperstimulation syndrome, polycystic ovary syndrome | Eugonia | Unknown | No outcome recorded |
| Phase 4 | NCT00417066 | Sep 2003 → Jul 2006 | female infertility, primary ovarian failure | Eugonia | Completed | No outcome recorded |
| Phase 4 | NCT00438217 | — | central precocious puberty | University of Pisa | Unknown | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT05746806 | Mar 2023 → Nov 2027 expected | prostate carcinoma | Insel Gruppe AG, University Hospital Bern | Active not recruiting | No outcome recorded |
| — | NCT05567731 | Oct 2022 → Dec 2023 | infertility disorder | Tanta University | Completed | No outcome recorded |
| — | NCT03291821 | Dec 2017 → Dec 2019 | female infertility | IVI Madrid | Completed | No outcome recorded |
| — | NCT02940535 | Dec 2016 → Dec 2019 | anovulation, female infertility | Navy General Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT02681536 | Feb → Sep 2016 | infertility disorder | Woman's Health University Hospital, Egypt | Unknown | No outcome recorded |
| — | NCT03006406 | Jan 2016 → Jan 2017 | — | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| — | NCT02477566 | Dec 2014 → Dec 2016 | polycystic ovary syndrome | Nanjing University | Unknown | No outcome recorded |
| — | NCT02400801 | Jun 2013 → Dec 2017 | endometriosis, female infertility | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| — | NCT01873378 | Jan 2013 → Aug 2015 | leiomyoma | Azienda Ospedaliera S. Maria della Misericordia | Completed | No outcome recorded |
| — | NCT01634724 | Jul 2012 | — | Nanjing University | Unknown | No outcome recorded |
| — | NCT02022241 | Jul 2012 → Dec 2015 | ovarian hyperstimulation syndrome | Chenshiling | Unknown | No outcome recorded |
| — | NCT01468441 | Sep 2011 → Mar 2012 | infertility disorder | Fertility - Assisted Fertilization Center | Completed | No outcome recorded |
| — | NCT00516490 | Sep 2006 → Jul 2007 | infertility disorder | V.K.V. American Hospital, Istanbul | Completed | No outcome recorded |
| — | NCT00375687 | Aug 2005 → Jan 2020 | prostate cancer | Kaunas University of Medicine | Unknown | No outcome recorded |
| — | NCT01764230 | Jan 2004 → Jul 2007 | Hodgkins lymphoma | Masaryk University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 92 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT07389187 Background | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05151016 Comparator | Dec 2021 → Dec 2023 | adenomyosis | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03192527 Background | Jun 2017 → Mar 2019 | female infertility | Alphamab Jilin Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04071574 Comparator | Feb 2018 → Aug 2019 | ectopic pregnancy, endometriosis, female infertility, hydrosalpinx +6 | Lebanese University | Completed | No outcome recorded |
| Phase 225 trials | ||||||
| Phase 2 | NCT07268794 Background | Nov 2025 → Apr 2027 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07254429 Comparator | Oct 2025 → Dec 2027 expected | postmenopausal osteoporosis | Martin Blomberg Jensen | Recruiting | No outcome recorded |
| Phase 2 | NCT06832774 Background | Aug 2025 → Dec 2027 expected | metastatic prostate carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06528210 Background | Apr 2025 → Jun 2026 | prostate adenocarcinoma | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT06734130 Background | Jan 2025 → Jan 2029 expected | metastatic prostate carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07553988 Background | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06378866 Comparator | Jun 2024 → Feb 2031 expected | castration-resistant prostate carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT05851547 Background | Nov 2023 → Jun 2027 expected | prostate neoplasm | Ottawa Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05555017 Background | Feb 2023 → Nov 2024 | prostate cancer | The Netherlands Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05982093 Comparator | Feb 2023 → Dec 2026 expected | hormone receptor-positive breast cancer | SOLTI Breast Cancer Research Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05498272 Background | Feb 2023 → Aug 2026 overdue | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, prostate adenocarcinoma | Rana McKay, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05212857 Background | Apr 2022 → Feb 2024 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05189457 Background | Jan 2022 → Jul 2027 expected | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04931342 Background | Oct 2021 → Feb 2028 expected | ovarian cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04992026 Background | Jan 2021 → Dec 2024 | metastatic prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 2 | NCT05406999 Background | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT03899077 Comparator | Apr 2019 → Aug 2025 | prostate cancer | Cancer Research Antwerp | Unknown | No outcome recorded |
| Phase 2 | NCT03944434 Background | Dec 2018 → Dec 2024 overdue | breast cancer | Fondazione Sandro Pitigliani | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04869371 Background | Dec 2018 → Dec 2020 | — | Hongqian Guo | Unknown | No outcome recorded |
| Phase 2 | NCT02278185 Comparator | Nov 2015 → Apr 2019 | prostate adenocarcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 2 | NCT02742675 Background | Sep 2015 → Mar 2021 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01973842 Comparator | Feb 2014 → Jul 2016 | infertility disorder | Aristotle University Of Thessaloniki | Unknown | No outcome recorded |
| Phase 2 | NCT02461875 Background | May 2013 → Nov 2015 | ovarian hyperstimulation syndrome | Aljazeera Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01732094 Background | Jul 2012 → May 2013 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 2 | NCT01732068 Background | Jul 2012 → May 2013 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 expected | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03353883 Comparator | Jun 2017 → Jun 2018 | female infertility | Benha University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03139474 Comparator | Jun 2017 → Jun 2019 | female infertility | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02685397 Background | Oct 2016 → Apr 2027 expected | castration-resistant prostate carcinoma | Sir Mortimer B. Davis - Jewish General Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01590173 Comparator | Jan 2012 → Jul 2016 | infertility disorder | National and Kapodistrian University of Athens | Completed | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT07477626 Background | Mar 2026 → Dec 2033 expected | metastatic malignant neoplasm in the lymph nodes, prostate cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05879926 Comparator | Oct 2023 → Jan 2032 expected | breast cancer | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05972902 Comparator | Jul → Dec 2023 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT05781217 Comparator | Mar → Dec 2023 overdue | prostate cancer | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | Recruiting | No outcome recorded |
| Phase 3 | NCT05050084 Background | Dec 2021 → Nov 2026 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04484818 Background | Mar 2021 → Sep 2026 expected | prostate carcinoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513717 Background | Jan 2021 → Dec 2033 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04557059 Background | Nov 2020 → Aug 2029 expected | prostate neoplasm | Janssen Pharmaceutica N.V., Belgium | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04423211 Background | Oct 2020 → Dec 2032 expected | metastatic prostate carcinoma, prostate adenocarcinoma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04181203 Background | Jan 2020 → Sep 2028 expected | prostate cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03767218 Background | Nov 2018 → May 2022 | female infertility | University Hospital Brussels | Completed | No outcome recorded |
| Phase 3 | NCT03678025 Background | Sep 2018 → Apr 2028 expected | prostate adenocarcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT01546987 Background | May 2012 → Nov 2021 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01313273 Background | Jun 2011 → Jun 2013 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 3 | NCT01402336 Comparator | Jun 2011 → Dec 2016 | infertility disorder, polycystic ovary syndrome | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01125488 Background | Mar 2008 → Mar 2009 | endometriosis | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 3 | NCT00725491 Comparator | May 2007 → Dec 2008 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00288080 Background | Dec 2005 → Apr 2014 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00412022 Background | Mar 2004 → Nov 2024 | breast cancer | National Cancer Institute, Naples | Unknown | No outcome recorded |
| Phase 3 | NCT00066703 Background | Nov 2003 → Mar 2011 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 3 | NCT00764166 Background | Jun 2003 → Nov 2009 | prostate adenocarcinoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT00004054 Background | Jan 2000 → Apr 2010 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT06763926 Comparator | Jun 2026 → Jan 2028 expected | — | Fundacion Dexeus | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06175832 Background | Jan 2025 → Dec 2027 expected | — | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT06396390 Background | Aug 2024 → Jun 2026 overdue | infertility disorder | Nesta Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04157725 Comparator | Jun 2023 → Jan 2025 | infertility disorder, polycystic ovary syndrome | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05321511 Comparator | Mar → Dec 2022 | ovarian dysfunction | Instituto Bernabeu | Unknown | No outcome recorded |
| Phase 4 | NCT04992468 Background | Oct 2021 → Apr 2023 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| Phase 4 | NCT04727684 Comparator | Aug 2020 → Feb 2022 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04724486 Comparator | Aug 2020 → Mar 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04724343 Comparator | Dec 2019 → Jan 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727671 Comparator | Dec 2019 → Aug 2021 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT03784404 Comparator | Dec 2018 → Dec 2019 | ovarian endometriosis | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03118830 Comparator | Apr → Nov 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02821819 Background | Jan 2017 → Jan 2018 | infertility disorder | Instituto Bernabeu | Terminated | No outcome recorded |
| Phase 4 | NCT02312076 Comparator | Sep 2016 → Dec 2024 | infertility disorder | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT02312089 Comparator | Aug 2016 → Dec 2024 | infertility disorder | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT04008966 Comparator | Jul 2016 → Jun 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02330770 Comparator | Jun 2016 → Dec 2024 | infertility disorder | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT02102646 Comparator | Apr 2014 → Oct 2015 | fatty liver disease, hypogonadism, metabolic syndrome X, prostate cancer | Herlev Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01753297 Comparator | Dec 2012 → Sep 2019 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 4 | NCT01581359 Comparator | Mar 2012 → Mar 2015 | endometriosis, infertility disorder | La Fe Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01607203 Comparator | Nov 2011 → Dec 2013 | infertility disorder | AZ Jan Palfijn Gent | Completed | No outcome recorded |
| Phase 4 | NCT01161563 Comparator | Jul 2010 → Apr 2011 | prostate cancer | Watson Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT06913075 Comparator | Jun → Jul 2026 overdue | adenomyosis | Indira IVF Hospital Pvt Ltd | Not yet recruiting | No outcome recorded |
| — | NCT06481696 Comparator | Jun 2024 → Dec 2025 | infertility disorder | Andros Day Surgery Clinic | Unknown | No outcome recorded |
| — | NCT07128394 Background | Feb 2024 → Sep 2026 expected | female infertility | Nanjing University | Recruiting | No outcome recorded |
| — | NCT06581679 Comparator | Dec 2023 → Apr 2024 | adenomyosis | Zagazig University | Completed | No outcome recorded |
| — | NCT05521828 Background | Apr 2023 → Sep 2024 | — | CRG UZ Brussel | Unknown | No outcome recorded |
| — | NCT05112692 Comparator | Nov 2021 → Nov 2023 | polycystic ovary syndrome | Mansoura University | Unknown | No outcome recorded |
| — | NCT03684824 Background | Sep 2018 → Sep 2019 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT03142035 Comparator | Oct 2017 → Feb 2023 | endometriosis | American University of Beirut Medical Center | Unknown | No outcome recorded |
| — | NCT04846218 Comparator | Dec 2016 → Jan 2020 | female infertility | Ain Shams University | Completed | No outcome recorded |
| — | NCT02635607 Background | Jan → Dec 2016 | female infertility | Chong Qing Reproducive and Genetic Institute | Unknown | No outcome recorded |
| — | NCT02208986 Comparator | Aug 2014 → Feb 2015 | — | Vietnam National University | Completed | No outcome recorded |
| — | NCT02022228 Background | Jul 2012 → Dec 2015 | ovarian hyperstimulation syndrome | Chenshiling | Unknown | No outcome recorded |
| — | NCT01565265 Comparator | Apr → Dec 2012 | female infertility | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-06-12 | Ipsen | Debiopharm and Ipsen extend their strategic Decapeptyl® (triptorelin) partnership for another 15 years ipsen.com ↗ |
Evidence & citations 30 cited values
Every value below carries the sentence it was read from. 207 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triptorelin | “All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing...” NCT01368588 ↗181“When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗ “This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗ “GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa...” NCT01634724 ↗ “Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used...” NCT03139474 ↗ “A multi-center, randomized controlled clinical trial of the application of a shortened protocol of long-acting Triptorelin down-regulated prior to IVF/ICSI among patients with...” PMID 30572916 ↗ Dec 2018 “Group II (Dual trigger group) that included 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2...” NCT04008966 ↗ “the agonist group will receive Decapeptyl® 0.1 mg (triptorelin) starting in the mid-luteal phase of the natural cycle until downregulation until the day of ovulation induction” NCT01565265 ↗ “Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle” NCT03684824 ↗ “Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle.” NCT03940807 ↗ “HCG (10000 IU /IM) and triptorelin (0.2 mg/S.C) are administered 36 hours before ovum pickup . Moreover, 0.1mg of triptorelin is administered 24 h prior to ovum pick-up.” NCT07569302 ↗ “Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression.” NCT01313273 ↗ “Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration.” NCT02461875 ↗ “Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM” NCT02330770 ↗ “Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.” NCT01603420 ↗ “Will receive routine LPS and additional single GnRH-a bolus, triptorelin 0.1 mg subcutaneous injection on the 6th day after oocyte retrieval.” NCT05286554 ↗ “Triptorelin Acetate for Injection (or similar drugs): 3.75 mg per vial, intramuscular injection once every 4 weeks as one treatment course.” NCT07319429 ↗ “Androgen deprivation therapy includes available GnRH agonists and antagonists, such as Triptorelin, Leuprolide, Goserelin and Degarelix.” NCT07477626 ↗ “Hypodermic injection of Luteinizing Hormone-Releasing Hormone Analog every 4 weeks including goserelin, leuprolide, triptorelin ect.” NCT04992026 ↗ “Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle.” NCT03784404 ↗ “Triptorelin (0.2 mg/S.C ) and HCG (10000 IU/I.M) are administered 38 to 39 h and 35 to 36 h prior to ovum pick-up., respectively.” NCT07569289 ↗ “LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration” NCT00528866 ↗ “Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)” NCT04992468 ↗ “gonadotropin-releasing hormone agonist ("Leuprorelin", "Goserelin" or "Triptorelin") 3.75mg/28d injection subcutaneously” NCT05945407 ↗ “luteinizing hormone-releasing hormone (LHRH) agonist (e.g., leuprolide acetate, goserelin, buserelin, or triptorelin)” NCT00288080 ↗ “ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.” NCT03511196 ↗ “gonadotropin-releasing hormone analog (leuprolide, goserelin, or triptorelin as determined by treating physician)” NCT03279250 ↗ “Maintenance of ADT using GnRH agonist or antagonist (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix).” NCT07389187 ↗ “Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months” NCT00004054 ↗ “LHRH agonist (antagonist) therapy consists of leuprolide, goserelin, buserelin, triptorelin, or degarelix.” NCT00936390 ↗ “Standard HRT protocol + Triptorelin 0.1mg subcutaneous injection, administered once 30-60 minutes af” NCT07653282 ↗ “Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months.” NCT05879926 ↗ “GNRH agonist (leuprolide, goserelin, triptorelin) or GNRH antagonist (relugolix, degarelix)” NCT06528210 ↗ “GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup.” NCT07569315 ↗ “Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable.” NCT04931342 ↗ “* Triptorelin: lyophilisate for solution for intramuscular injection, 3.75 mg, or” NCT07553988 ↗ “GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.” NCT02821819 ↗ “Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.” NCT03944434 ↗ “Gonadotropin-Releasing Hormone agonist (Triptorelin 0.3 mg subcutaneous once)” NCT04224818 ↗ “GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom)” NCT04407052 ↗ “GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom)” NCT04407065 ↗ “with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany)” NCT01590173 ↗ “Triptorelin Acetate 3.75mg for two consecutive dosage at 30 days interval” NCT06913075 ↗ “Available drugs include triptorelin, goserelin, leuprolide, digareke ect.” NCT05406999 ↗ “a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg)” PMID 32290838 ↗ Apr 2020 “This includes leuprolide, goserelin, triptorelin, and degarelix.” NCT02972060 ↗ “Triptorelin was given by injection for 4 times every 3 months” NCT00764166 ↗ “one subcutaneous depot of 22,5mg triptorelin (Pamorelin)” NCT05555017 ↗ “GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose)” NCT04157725 ↗ “Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland)” NCT05567731 ↗ “leuprolide, goserelin, buserelin, or triptorelin” NCT01492972 ↗ “GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C )” NCT06146413 ↗ “e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.” NCT05746806 ↗ “Arvekap 0.1 mg (Triptorelin, Ipsen, France)” NCT00417183 ↗ “Arvekap 0.1mg (Triptorelin, Ipsen, France)” NCT00417066 ↗ “Decapeptyl® SR 22.5mg (Triptorelin)” NCT01673984 ↗ “3.75 mg triptorelin im. q28d” NCT03397537 ↗ “triptorelin” NCT07128394 ↗ “Triptorelin” NCT05189457 ↗ “Triptorelin” NCT05498272 ↗ “Triptorelin” NCT06734130 ↗ |
| Known as | Arvekap | “Arvekap 0.1mg (Triptorelin, Ipsen, France)” NCT00417144 ↗ |
| Known as | Decapeptyl | “When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗10“the agonist group will receive Decapeptyl® 0.1 mg (triptorelin) starting in the mid-luteal phase of the natural cycle until downregulation until the day of ovulation induction” NCT01565265 ↗ “In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (Triptorelin, Decapeptyl 0.1 mg, Ipsen S.p.A., Italy) 0.3 mg subcutaneously” NCT06481696 ↗ “Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle.” NCT03809221 ↗ “One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.” NCT01020448 ↗ “Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)” NCT00415246 ↗ “Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)” NCT04992468 ↗ “GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom)” NCT04407052 ↗ “Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland)” NCT05567731 ↗ “Drug: Triptorelin (Decapeptyl®)” NCT00444639 ↗ “Decapeptyl (Triptorelin)” NCT02940535 ↗ |
| Known as | Decapeptyl 0.1 mg | “GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.” NCT05397795 ↗ |
| Known as | Decapeptyl Daily | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01607203 ↗ |
| Known as | DECAPEPTYL LP | “Triptorelin (DECAPEPTYL LP 3 mg, IPSEN)” NCT02856048 ↗ |
| Known as | Decapeptyl SR | “Triptorelin pamoate 11.25mg (Decapeptyl® SR)” NCT00564850 ↗1“Decapeptyl® SR 22.5mg (Triptorelin)” NCT01673984 ↗ |
| Known as | Dipherelin | “Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle.” NCT03809221 ↗ |
| Known as | Diphereline | “Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks.” NCT04869371 ↗1“Diphereline (Triptorelin embonate)” NCT02940535 ↗ |
| Known as | FP-014 | “FP-014, 22.5 mg (Triptorelin Mesylate Injection, 22.5 mg)” NCT06795191 ↗ |
| Known as | GnRH analog | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03291821 ↗ |
| Known as | Gonapeptyl | “For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH,...” NCT06396390 ↗8“Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart” NCT03169166 ↗ “gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter.” NCT03115307 ↗ “Oocyte maturation trigger with GnRH agonist (0.2mg Gonapeptyl) in both groups.” NCT03767218 ↗ “GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose)” NCT04157725 ↗ |
| Known as | Gonapetpyl | “with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany)” NCT01590173 ↗ |
| Known as | Long-acting Triptorelin on pituitary down-regulation | “Long-acting Triptorelin on pituitary down-regulation” NCT02477566 ↗ |
| Known as | Pamorelin | “The active ingredient of Pamorelin® 11,25 mg is Triptorelin.” NCT00444639 ↗1“one subcutaneous depot of 22,5mg triptorelin (Pamorelin)” NCT05555017 ↗ |
| Known as | Pamorelin LA | “Applications of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Patients With Advanced Prostate Cancer” NCT01257425 ↗1“e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.” NCT05746806 ↗ |
| Known as | Trelstar | “Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock.” NCT01161563 ↗ |
| Known as | triptorelin (Diphereline SR 3 mg, Ibsen) | “triptorelin (Diphereline SR 3 mg, Ibsen)” NCT01764230 ↗ |
| Known as | triptorelin acetate | “Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the...” NCT04557059 ↗19“For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH,...” NCT06396390 ↗ “Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle” NCT03684824 ↗ “Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle.” NCT03940807 ↗ “Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.” NCT02244151 ↗ “Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.” NCT06487143 ↗ “gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter.” NCT03115307 ↗ “GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom)” NCT04407052 ↗ “with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany)” NCT01590173 ↗ “leuprolide, goserelin, triptorelin acetate” NCT04181203 ↗ “Drug: Triptorelin acetate” NCT04724343 ↗ “Drug: triptorelin acetate” NCT01007851 ↗ |
| Known as | Triptorelin Acetate PR 1-month | “the standard of care, triptorelin acetate PR 1-month” PMID 35947347 ↗ Aug 2022 |
| Known as | Triptorelin embonate | “Diphereline (Triptorelin embonate)” NCT02940535 ↗ |
| Known as | triptorelin embonate (pamoate) | “Each patient received two consecutive intramuscular injections of triptorelin embonate (pamoate) 22.5 mg at an interval of 24 weeks.” PMID 19888782 ↗ 2009 |
| Known as | Triptorelin Mesylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06795191 ↗ |
| Known as | triptorelin pamoate | “The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or...” NCT05590793 ↗9“A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169” NCT05458856 ↗ “Applications of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Patients With Advanced Prostate Cancer” NCT01257425 ↗ “Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.” NCT06487143 ↗ “Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock.” NCT01161563 ↗ “Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks.” NCT04869371 ↗ “Triptorelin pamoate 11.25mg (Decapeptyl® SR)” NCT00564850 ↗ “Triptorelin Pamoate 11.25mg” NCT01715129 ↗ “Drug: Triptorelin pamoate” NCT00124514 ↗ “Triptorelin pamoate 15mg” NCT04736602 ↗ |
| Known as | Triptorelin SR | “A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with...” PMID 32290838 ↗ Apr 2020 |
| Known as | triptorelin: Diphereline | “triptorelin: Diphereline” NCT02022228 ↗ |
| Known as | Tryptorelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00503217 ↗ |
| Action | Inhibit | “Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens.” NCT00003026 ↗ |
| Modality | Other / unclassified | “a Gonadotrophin Releasing Hormone Analogue” NCT00415246 ↗ |
| Route | Intramuscular | “triptorelin IM once a month” NCT00003734 ↗ |